GHRP-2

Researchers and clinicians study GHRP-2 primarily to understand its biological interactions, receptor binding affinity, and potential role within its biochemical class.

GHRP-2 interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a growth hormone secretagogue; synthetic hexapeptide containing d-amino acids and 2-naphthylalanine.

Evidence for GHRP-2 is currently derived primarily from laboratory or preclinical models. Consult the published evidence file for specific indexed studies.

Controlled human clinical trials evaluating GHRP-2 for therapeutic efficacy, safety, and pharmacokinetics are limited or absent in peer-reviewed Western registries.

What Has Actually Been Studied

Preparation and Handling

Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.

United States Regulatory Status

FDA compounding Category 2

• No approved drug product exists in Drugs@FDA.
• Listed by FDA as “Growth hormone releasing peptide-2 (GHRP-2)” on the active Category 2 table for 503B compounding, for injectable and nasal routes of administration, added 29 September 2023.
• FDA's published concerns include immunogenicity risk from aggregation and peptide-related impurities, the added characterisation complexity of an unnatural amino acid, and reports of serious adverse events in patients who received GHRP-2.
• No registered studies were returned by ClinicalTrials.gov for the intervention name GHRP-2 at review.